AstraZeneca gets FDA approval for Farxiga to treat heart failure
Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor intended to treat heart failure with reduced ejection fraction in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 May 20
Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor intended to treat heart failure with reduced ejection fraction in…
06 May 20
Pfizer and BioNTech have partnered to advance the development of multiple Covid-19 vaccine candidates into human clinical testing
05 May 20
Lilly will receive an exclusive license for clinical development, manufacturing and distribution of products outside of Greater China,…
05 May 20
Stemline’s ELZONRIS is an FDA-approved and commercially available targeted therapy to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN)
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 May 20
The FD authorisation will enable the use of remdesivir to treat hospitalised patients with severe Covid-19 disease in…
01 May 20
The collaboration between AstraZeneca and Oxford University will enable global development, manufacturing and distribution of the new COVID-19…
30 Apr 20
Zejula is an oral monotherapy used as treatment for women regardless of BRCA mutational status, addressing a high…
30 Apr 20
Supernus will acquire APOKYN, MYOBLOC, and XADAGO, along with Apomorphine Infusion Pump, which is currently under late-stage development
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Apr 20
FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants…
29 Apr 20
Cosentyx is indicated for patients with non-radiographic axial spondyloarthritis (nr-axSpA), a part of the axial spondyloarthritis (axSpA) disease…